Evaxion A (EVAX) Return on Sales (2024 - 2025)

Evaxion A (EVAX) posted Return on Sales of 0.02% for Q1 2026, down 22.01% quarter-over-quarter from 0.01% in Q4 2025, and up 3.0% year-on-year from 0.01% in Q1 2025.

Evaxion A (EVAX) Return on Sales (2024 - 2025) Analysis & Trends

Evaxion A (EVAX) has reported Return on Sales for 3 consecutive years, with 0.02% the latest figure, recorded in Q1 2026.

  • Return on Sales for Q1 2026 came in at 0.02%, up 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.02% (up 3.0% YoY), and the FY2025 annual result was 0.01%, up 2.0% from the prior year.
  • Return on Sales was 0.02% for Q1 2026 at Evaxion A, down from 0.01% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.15% in Q1 2024 and troughed at 1.41% in Q2 2025.
  • Average Return on Sales over 3 years is 0.23%, with a median of 0.02% recorded in 2026.
  • The widest YoY moves for Return on Sales: up 33 bps in 2025, down 98 bps in 2025.
  • Over 3 years, Return on Sales stood at 0.34% in 2024, then soared by 96 bps to 0.01% in 2025, then decreased by 22 bps to 0.02% in 2026.
  • Per Business Quant data, the three most recent Return on Sales figures were 0.02% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Genmab A 276,399.99 Bn 276,398.47 Bn 831.00 Mn -
2 Akari Therapeutics 1,217.26 Bn 1,217.26 Bn - -
3 BeOne Medicines 419.38 Bn 414.59 Bn 1.35 Bn 0.00%
4 Vertex Pharmaceuticals 126.54 Bn 119.30 Bn 2.59 Bn 0.00%
5 Pharming 110.17 Bn 110.12 Bn 65.80 Mn 0.00%
6 Regeneron Pharmaceuticals 64.97 Bn 56.22 Bn 3.31 Bn 0.00%
7 Argenx Se 56.44 Bn 56.44 Bn 1.18 Bn 0.00%
8 Alnylam Pharmaceuticals 40.09 Bn 37.08 Bn 959.66 Mn 0.00%
9 Revolution Medicines 37.15 Bn 37.15 Bn - -
10 Evaxion A 1.33 Bn 1.33 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 -1.41%
Sep 30, 2024 -0.01%